Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: A single-institution analysis

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 101-108

  Dieci, M V ^a   Barbieri, E ^a   Piacentini, F ^a   Ficarra, G ^a   Bettelli, S ^a   Dominici, M ^a   Conte, P F ^a   Guarneri, V ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Breast cancer; Discordance; HER2; Hormone receptors; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; LAPATINIB; NERATINIB; PROGESTERONE RECEPTOR; TRASTUZUMAB EMTANSINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSTITUTIONAL CARE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84871533350     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds248     Document Type: Article

References (38)

1. SØrlie T. Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
2. Perou CM, SØrlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
4. Perez EA, Romond EH, Suman VJ. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2- positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B- 31. J Clin Oncol 2011; 29: 3366-3373.
5. Khasraw M, Brogi E, Seidman AD. The need to examine metastatuic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep 2011; 13: 17-25.
6. Broom RJ, Tang PA, Simmons C et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009; 29: 1557-1562.
7. Liedtke C, Broglio K, Moulder S et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009; 20: 1953-1958.
8. Curigliano G, Bagnardi V, Viale G et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011; 22: 2227-2233.
9. Hoefnagel LD, van de Vijver MJ, van Slooten HJ et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010; 12: R75.
10. Macfarlane R, Seal M, Speers C et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist 2012 [Epub ahead of print].
11. Lower EE, Glass EL, Bradley DA et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005; 90: 65-70.
12. Lower EE, Glass E, Blau R et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009; 113: 301-306.
13. St Romain P, Madan R, Tawfik OW et al. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. Hum Pathol 2012; 43: 398-404.
14. Botteri E, Disalvatore D, Curigliano G et al. Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast 2011 [Epub ahead of print].
15. Guarneri V, Giovanelli S, Ficarra G et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13: 838-844.
16. NCCN Clinical Practice Guidelines in Oncology, Breast Cancer. Version 1.2012. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. (5 March 2012, date last accessed).
17. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30: 587-592.
18. Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissue study (BRITS). Breast Cancer Res 2010; 12: R92.
19. Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009; 20: 1499-1504.
20. Karlsson E, Lindstrom LS, Wilking U et al. Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 2010; 28: 116s (suppl; abstr 1009).
21. Wilking U, Karlsson E, Skoog L et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 2011; 125: 553-561.
22. Pusztai L, Viale G, Kelly CM et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010; 15: 1164-1168.
23. Bertos NR, Park M. Breast cancer-one term, many entities? J Clin Invest 2011; 121: 3789-3796.
24. WU JM, Fackler MU, Haluska MK et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008; 14: 1938-1946.
25. Pectasides D, Gaglia A, Arapantoni-Dadioti P et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006; 26: 647-653.
26. Mittendorf EA, WU Y, Scaltriti M et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009; 15: 7381-7388.
27. Weigelt B, Glas AM, Wessels LF et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 2003; 100: 15901-15905.
28. Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
29. Amir E, Clemons M, Purdie CA et al. Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2011 [Epub ahead of print].
30. Richter S, Zandvakili A. Meta analysis of discordant HER2 status in matched primary and metastatic breast cancer. Cancer res 2011; 71: 134s, (24 Suppl. abstr PD05-05).
31. Niikura N, Liu J, Hayashi N et al. Loss of human epodermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressin primary breast tumors. J Clin Oncol 2012; 30: 593-599.
32. Bogina G, Bortesi L, Marconi M et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 2011; 459: 1-10.
33. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
34. Iwamoto T, Booser DL, Valero V et al. Estrogen Receptor (ER) mRNA and ERRelated Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. J Clin Oncol 2012; 30: 729-734.
35. Raghav KPS, Hernandez-Aya LF, Lei X et al. Impact of low estrogen- and progesterone-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers. J Clin Oncol 2011; 29 (suppl; abstr 1023).
36. Lindstrom L, Howell S, Astrom G et al. Controversies in the management of metastatic breast cancer: Biologic evaluation of breast cancer-should metastases be biopsied? Am Soc Oncol Ed Book 2010; e7-e12.
37. O'Shaughnessy J, Craig DW, Kiefer J et al. Next generation sequencing reveals co-activating events in the MAPK and P13K/AKT pathways in metastatic triple negative breast cancers. Cancer res 2011; 71: 105s (24 suppl, abstr S3-5).
38. Andre F, delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection?. J Clin Oncol 2011; 20: 1236-1238.